相似文献
1
Is tumor microenvironment important for targeted therapy in lung cancer?
Cancer Lett. 2024 Nov 1;604:217203. doi: 10.1016/j.canlet.2024.217203. Epub 2024 Sep 3.
2
[The targets research of non-small cell lung cancer targeted therapy].
Zhongguo Fei Ai Za Zhi. 2013 Feb;16(2):107-13. doi: 10.3779/j.issn.1009-3419.2013.02.09.
3
Immunotherapy in non-small cell lung cancer harbouring driver mutations.
Cancer Treat Rev. 2021 May;96:102179. doi: 10.1016/j.ctrv.2021.102179. Epub 2021 Mar 19.
4
PD-1 Axis Inhibitors in EGFR- and ALK-Driven Lung Cancer: Lost Cause?
Clin Cancer Res. 2016 Sep 15;22(18):4539-41. doi: 10.1158/1078-0432.CCR-16-1401. Epub 2016 Jul 28.
5
Interleukin-1 in tumor progression, therapy, and prevention.
Cancer Cell. 2021 Aug 9;39(8):1023-1027. doi: 10.1016/j.ccell.2021.04.011. Epub 2021 May 13.
6
The Metabolic Remodelling in Lung Cancer and Its Putative Consequence in Therapy Response.
Adv Exp Med Biol. 2020;1219:311-333. doi: 10.1007/978-3-030-34025-4_16.
7
Identification of SMARCAL1 as a molecular target for small cell lung cancer treatment.
Cancer Lett. 2024 Jun 28;592:216932. doi: 10.1016/j.canlet.2024.216932. Epub 2024 May 11.
8
Tumor-intrinsic response to IFNγ shapes the tumor microenvironment and anti-PD-1 response in NSCLC.
Life Sci Alliance. 2019 May 27;2(3). doi: 10.26508/lsa.201900328. Print 2019 Jun.
9
Therapeutic targeting of TGF-β in lung cancer.
FEBS J. 2025 Apr;292(7):1520-1557. doi: 10.1111/febs.17234. Epub 2024 Jul 31.
10
Three cheers for targeted therapy in non-small cell lung cancer... When we hit the target!
J Chemother. 2011 Aug;23(4):245-6. doi: 10.1179/joc.2011.23.4.245.
本文引用的文献
1
Understanding the dynamics of TKI-induced changes in the tumor immune microenvironment for improved therapeutic effect.
J Immunother Cancer. 2024 Jun 21;12(6):e009165. doi: 10.1136/jitc-2024-009165.
2
Efficacy of Lorlatinib in Treatment-Naive Patients With ALK-Positive Advanced NSCLC in Relation to EML4::ALK Variant Type and ALK With or Without TP53 Mutations.
J Thorac Oncol. 2023 Nov;18(11):1581-1593. doi: 10.1016/j.jtho.2023.07.023. Epub 2023 Aug 3.
3
Current literature review on the tumor immune micro-environment, its heterogeneity and future perspectives in treatment of advanced non-small cell lung cancer.
Transl Lung Cancer Res. 2023 Apr 28;12(4):857-876. doi: 10.21037/tlcr-22-633. Epub 2023 Mar 17.
4
Lung cancer immunotherapy: progress, pitfalls, and promises.
Mol Cancer. 2023 Feb 21;22(1):40. doi: 10.1186/s12943-023-01740-y.
5
Third-generation EGFR and ALK inhibitors: mechanisms of resistance and management.
Nat Rev Clin Oncol. 2022 Aug;19(8):499-514. doi: 10.1038/s41571-022-00639-9. Epub 2022 May 9.
6
Aspirin Suppressed PD-L1 Expression through Suppressing KAT5 and Subsequently Inhibited PD-1 and PD-L1 Signaling to Attenuate OC Development.
J Oncol. 2022 Mar 29;2022:4664651. doi: 10.1155/2022/4664651. eCollection 2022.
7
Tumor immune microenvironment in epidermal growth factor receptor-mutated non-small cell lung cancer before and after epidermal growth factor receptor tyrosine kinase inhibitor treatment: a narrative review.
Transl Lung Cancer Res. 2021 Sep;10(9):3823-3839. doi: 10.21037/tlcr-21-572.
8
Membrane-Associated RING-CH 8 Functions as a Novel PD-L1 E3 Ligase to Mediate PD-L1 Degradation Induced by EGFR Inhibitors.
Mol Cancer Res. 2021 Oct;19(10):1622-1634. doi: 10.1158/1541-7786.MCR-21-0147. Epub 2021 Jun 28.
9
Concurrent use of aspirin with osimertinib is associated with improved survival in advanced EGFR-mutant non-small cell lung cancer.
Lung Cancer. 2020 Nov;149:33-40. doi: 10.1016/j.lungcan.2020.08.023. Epub 2020 Sep 9.
10
Therapy-Induced Evolution of Human Lung Cancer Revealed by Single-Cell RNA Sequencing.
Cell. 2020 Sep 3;182(5):1232-1251.e22. doi: 10.1016/j.cell.2020.07.017. Epub 2020 Aug 20.
Zotero 插件